Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End

Syndax Pharmaceuticals SNDX and Incyte Corporation INCY announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy

The trial achieved its primary endpoint across all cohorts, with patients treated with axatilimab at doses of 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks, and 3.0 mg/kg every four weeks demonstrating overall response rates (ORR) within the first six months of treatment of 74%, 67%, and 50%, respectively.

Also Read: Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape.

Responses were achieved across key patient subgroups, including those with prior exposure to ruxolitinib, belumosudil and/or ibrutinib. 

Based on these results and pending agreement from the FDA, Syndax and Incyte intend to submit a Biologics License Application (BLA) to the FDA by year-end 2023.

The AGAVE-201 study enrolled 241 patients across 121 sites in 16 countries. 

Among responders treated with 0.3 mg/kg of axatilimab, 60% of patients maintained a response at 12 months. The median duration of response in this population has not been reached. 

Additionally, in the 0.3 mg/kg group, 55% of patients experienced a clinically meaningful improvement in symptoms, as measured by at least a seven-point decrease in the modified Lee chronic GVHD Symptom Scale score. 

Price Action: SNDX shares are down 1.03% at $21.04, and INCY stock is down 0.80% at $63.64 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!